Related Experiment Video

Updated: Sep 26, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

69.5K

Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing

Marta Wolosowicz1, Slawomir Prokopiuk2, Tomasz W Kaminski3

  • 1Department of Physiology, Medical University of Bialystok, 15-222 Bialystok, Poland.

Medicina (Kaunas, Lithuania)
|April 23, 2022
PubMed

Insights

This review highlights recent advances in treating insulin resistance (IR), a key factor in Type 2 Diabetes Mellitus (T2DM). It summarizes new therapeutic strategies for managing this complex metabolic dysfunction.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Diabetes Mellitus (DM) is a leading cause of global mortality, characterized by hyperglycemia due to insulin resistance (IR) or inadequate insulin secretion.
  • Insulin Resistance (IR) is central to Type 2 Diabetes Mellitus (T2DM), leading to hyperglycemia, cardiovascular issues, inflammation, and metabolic syndrome.
  • Despite progress, IR remains a significant challenge, driving the need for novel and effective therapeutic interventions.

Purpose of the Study:

  • To provide a comprehensive overview of recent advancements in the treatment of insulin resistance.
  • To critically analyze new therapeutic approaches for IR based on literature published between February 2021 and March 2022.
  • To offer insights into the evolving landscape of IR management.

Main Methods:

  • Literature search conducted across major databases: MEDLINE/PubMed, Google Scholar, SCOPUS, and Clinical Trials Registry.
  • Selection criteria focused on recently published papers (February 2021 - March 2022) relevant to IR treatment.
  • Systematic review and synthesis of findings on novel therapeutic strategies for IR.

Main Results:

  • Recent research has yielded promising new therapeutic avenues for managing insulin resistance.
  • Advances include novel pharmacological agents and therapeutic strategies targeting the complex pathways of IR.
  • The review synthesizes key findings from recent studies, highlighting progress in effective IR treatment.

Conclusions:

  • The field of insulin resistance treatment is rapidly evolving, with significant recent progress.
  • Emerging therapies offer potential for more precise, safe, and effective management of IR and T2DM.
  • Continued research and clinical application of these advances are crucial for combating the global burden of diabetes.
Keywords:
glucose metabolisminsulin resistancemetabolic syndromeobesitytype 2 diabetes

More Related Videos

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.0K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.3K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.6K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
424
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
319
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
449
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
273
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
285